Keepspharma Achieves 59.4 Billion Won in Q1 Sales, Up 46% YoY... "Growth Momentum Continues"

Keeps Biopharma (Keepspharma) continued its rapid growth trajectory in the first quarter of this year, recording its highest-ever quarterly sales. Analysts attribute this performance to the full reflection of its business restructuring and a series of mergers and acquisitions (M&A).

According to the Financial Supervisory Service's electronic disclosure system on May 15, Keepspharma posted consolidated sales of 59.4 billion won in the first quarter of this year. This figure represents a 46% increase compared to 40.6 billion won in the same period last year. During the same period, the company recorded an operating loss of 700 million won and a net profit of 5.7 billion won.

Growth in standalone results was even more remarkable. Standalone sales for the first quarter reached 10.5 billion won, approximately 21 times higher than the 500 million won recorded in the same period last year.

The company cited the effects of restructuring its business to focus on pharmaceuticals and biotechnology as the main driver of this growth. Last year, Keepspharma completed its transformation into a pharmaceutical company through the absorption merger with Korea Global Pharmaceutical, and has since expanded its business scope into a comprehensive healthcare company by acquiring platform development biotech firms and pharmaceutical distribution companies in succession.

Annual sales growth has also shown a steep upward trend. Keepspharma's annual sales rose steadily from 14.6 billion won in 2022, to 92.1 billion won in 2023, 127.6 billion won in 2024, and 170.1 billion won in 2025. The average sales growth rate over the past three years has been around 46%.

The company is aiming to break its record for best-ever performance again this year. Factors cited for further earnings improvement include enhanced profitability by internalizing pharmaceutical distribution channels, expanding new products focused on anticancer drugs, and the effect of expanding Battery Solutions, which serves as a cash cow within the group.

Development of key pipelines is also accelerating. The next-generation targeted anticancer drug Idetrexate is undergoing combination clinical trials led by the UK Cancer Research Institute, while monotherapy clinical trials are also preparing to enter Phase 2 in South Korea and Europe in the second half of this year.

Regarding the peptide drug oral platform Oral-Loyd, discussions on collaboration with global big pharma companies are underway. The company also plans to attend major international conferences and events, such as BIO USA in June and the European Association for the Study of Diabetes in September.

Additionally, it has been reported that overseas clinical trials for its oral insulin, which has achieved world-class bioavailability, are in the final preparation stages.

Ha Yong Kim, CEO, stated, "The strategies we have pursued to improve the company's fundamentals and secure long-term growth engines are now translating into results," adding, "We will further accelerate the development of our pipeline and clinical entry, backed by stable cash flow."

This performance demonstrates that Keepspharma is simultaneously strengthening both its external growth and future new drug development capabilities through pharmaceutical and biotech-focused restructuring and an aggressive M&A strategy.

This content was produced with the assistance of AI translation services.